Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology

ORCID: 0000-0002-9451-6037

Publication year:
All
11 - 20 out of 26Page size: 10
  1. 2022
  2. Published

    COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

    Holmstroem, R. B., Nielsen, Ole Haagen, Jacobsen, Søren, Riis, Lene Buhl, Theile, S., Bjerrum, Jakob Tveiten , Vilmann, Peter, Johansen, Julia Sidenius, Boisen, M. K., Eefsen, R. H. L., Svane, Inge Marie, Nielsen, Dorte Lisbet & Chen, I. M., 2022, In: Journal for ImmunoTherapy of Cancer. 10, 9

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

    Holmstroem, R. B., Dahl, E. K., Helms, Morten, Nielsen, H. V., Andersen, J. B., Bjerrum, Jakob Tveiten , Svane, Inge Marie, Ellebaek, E. & Seidelin, Jakob Benedict, 2022, In: BMJ Open Gastroenterology. 9, 1, 4 p., e000989.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

    Klausen, U., Grauslund, J. H., Jørgensen, N. G. D., Ahmad, S. M., Jonassen, M., Weis-Banke, S. E., Martinenaite, E., Pedersen, L. B., Lisle, T. L., Gang, Anne Ortved, Enggaard, L., Hansen, M., Holmström, M. O., Met, Özcan, Svane, Inge Marie, Niemann, Carsten, Pedersen, Lars Møller & Andersen, Mads Hald, 2022, In: Frontiers in Oncology. 12, 1023015.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

    Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A. M., Bentzen, A. K., Marquard, A. M., Szallasi, Z., McGranahan, N., Andersen, R., Nielsen, M., Jönsson, G. B., dqp123, dqp123, Svane, Inge Marie & Hadrup, S. R., 2022, In: Journal of Clinical Investigation. 132, 2, p. 1-16 150535.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Lauss, M., dqp123, dqp123, Svane, Inge Marie & Jönsson, G., 2022, In: Clinical Cancer Research. 28, 9, p. 1751–1758 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

    Lorentzen, C. L., Martinenaite, E., Kjeldsen, J. W., Holmstroem, R. B., Mørk, S. K., Pedersen, A. W., Ehrnrooth, E., Andersen, Mads Hald & Svane, Inge Marie, 2022, In: Frontiers in Immunology. 13, 1023023.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Clinical advances and ongoing trials on mRNA vaccines for cancer treatment

    Lorentzen, C. L., Haanen, J. B., Met, Özcan & Svane, Inge Marie, 2022, In: The Lancet Oncology. 23, 10, p. e450-e458

    Research output: Contribution to journal › Review › Research › peer-review

  9. Published

    Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

    Mork, S. K., Kadivar, M., Bol, K. F., Draghi, A., Westergaard, M. C. W., Skadborg, S. K., Overgaard, N., Sorensen, A. B., Rasmussen, I. S., Andreasen, L. V., Yde, C. W., Trolle, T., Garde, C., Friis-Nielsen, J., Norgaard, N., Christensen, D., Kringelum, J. V., dqp123, dqp123, Hadrup, S. R. & Svane, Inge Marie, 31 Dec 2022, In: OncoImmunology. 11, 1, 15 p., 2023255.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Coexisting Alterations of MHC Class I Antigen Presentation and IFNg Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy

    Nielsen, M., Presti, M., Sztupinszki, Z., Jensen, Agnete Witness Præst, Draghi, A., Chamberlain, C. A., Schina, A., Yde, C. W., Wojcik, J., Szallasi, Z., Crowther, M. D., Svane, Inge Marie & Donia, M., 2022, In: Cancer Immunology Research. 10, 10, p. 1254-1262 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser

    Omland, S. H., Ejlertsen, J. S., Krustrup, D., Christensen, R. L., Svane, Inge Marie, Olesen, U. H. & Hædersdal, Merete, 2022, In: Cancers. 14, 23, 5815.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 Next

ID: 4054758